Catalyst
Slingshot members are tracking this event:
Johnson & Johnson (JNJ) expects to launch Phase III data on esketamine, an antidepressant, by late 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| JNJ | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 18, 2018
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT02417064
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Esketamine, Phase 3, Antidepressant
